The United States has released $600 million in previously frozen funding to Gavi, the Vaccine Alliance, reversing a decision announced by Health and Human Services Secretary Robert F. Kennedy Jr. in June 2025.
In a joint statement issued with the State Department, HHS said the money covers congressionally appropriated funds for both fiscal 2025 and fiscal 2026, and that the release follows commitments the administration secured from the alliance.
Two conditions came with it. Gavi committed to work toward transitioning away from vaccines preserved with mercury and toward mercury-free alternatives. And the statement said the United States "will not provide U.S. Government funding to the World Health Organization through Gavi."
Six Hundred Million Dollars and What It Buys
Gavi is a public-private partnership that pools donor money to purchase vaccines at negotiated prices for low- and middle-income countries and to support the systems that deliver them.
Its portfolio covers the immunizations that drive most childhood mortality reduction, including pentavalent vaccine against diphtheria, tetanus, pertussis, Haemophilus influenzae type b and hepatitis B, along with pneumococcal, rotavirus, measles, HPV, meningococcal A, and yellow fever vaccines. It also finances outbreak stockpiles, including for Ebola and cholera.
According to the alliance's own 2024 progress report, Gavi has supported the vaccination of more than 1.2 billion children since 2000 and estimates it has prevented 20.6 million deaths. Those are the organization's figures.
Congress appropriated $300 million for each of the two fiscal years at issue. The release followed a bipartisan push from Senate Appropriations Committee Chair Susan Collins and Vice Chair Patty Murray. Collins said in a statement that it was "welcome news that following our recent outreach" the department had committed the full amount, and framed the funding as helping stop outbreaks before they reach U.S. borders.
Thimerosal Sits at the Center of the Dispute
The condition attached to the money concerns thimerosal, a mercury-based preservative used in some multi-dose vaccine vials to prevent bacterial contamination after the vial is first punctured.
Multi-dose vials matter enormously in low-income settings, where they reduce cost per dose and simplify cold chain logistics. Removing the preservative generally means moving to single-dose presentations, which are more expensive and bulkier to ship.
The scientific question is settled in a way the political one is not. Thimerosal was removed from routine U.S. childhood vaccines beginning in 1999 as a precautionary measure, and the extensive research conducted since has not found evidence that it causes autism or other neurodevelopmental harm. Rates of autism diagnosis continued to rise after its removal.
The joint statement framed the transition as "a pro-vaccine, pro-innovation policy," and specified vaccines including meningococcal A, pentavalent, pneumococcal, and hepatitis B. Gavi has agreed to work toward the transition alongside its board and partner countries, and the statement acknowledged the shift will require manufacturers to expand production capacity and countries to adopt new formulations.
Public health groups have raised the practical concern rather than the scientific one: a preservative transition on a compressed timeline could constrain supply or raise costs in exactly the countries the alliance exists to serve.
A Claim in the Statement That Litigation Has Complicated
One assertion accompanying the announcement is worth flagging precisely because it is easy to repeat uncritically.
As Healio reported, the announcement stated that the United States no longer recommends any mercury-containing vaccines. That is not straightforwardly accurate. A federal judge in March blocked the votes taken by the reconstituted Advisory Committee on Immunization Practices, including the vote to remove thimerosal-containing vaccines from recommendations. The administration has appealed that ruling, which remains unresolved.
The practical effect for U.S. patients is minimal, since thimerosal-free formulations are standard here and single-dose presentations dominate. The point is narrower: the domestic policy the statement cites as settled is currently the subject of active litigation.
Gavi's Workaround on the WHO Restriction
The second condition drew a response that illustrates how donor restrictions function in practice.
The World Health Organization is a core Gavi partner, providing technical and programmatic support. Barring U.S. funds from reaching WHO through the alliance could, in principle, disrupt that arrangement.
Gavi's answer was accounting rather than confrontation. The alliance explained that WHO's role is already covered through existing funding from other international donors, and said U.S. money "will be focused on vaccine procurement, which is consistent with past practices." The restriction is legally binding on the alliance, and the alliance has structured its budget so that it changes little operationally.
That resolution is real, though it does not eliminate the underlying tension. It also underscores that Gavi's ability to absorb a restriction from one donor depends on other donors continuing to fund the parts the restriction touches.
The Connection Back to U.S. Households
Global immunization funding can feel remote from a household in Ohio or Texas, and the honest answer is that the pathway is real but indirect.
Vaccine-preventable diseases do not respect borders. Measles outbreaks in the United States have repeatedly originated with importations from countries where coverage lapsed, and the current U.S. measles count has reached a 35-year high. Gavi-supported programs and outbreak stockpiles reduce the pool of infection that international travel can carry home.
The more immediate action for American families remains domestic and unchanged. Confirm that your own household is current on recommended vaccines before the school year, and check destination-specific recommendations before international travel, since some routine vaccines are given earlier than usual for infants traveling to areas with active transmission.
For anyone following this policy area, the next verifiable developments are the disposition of the appeal over the ACIP votes and whatever Gavi publishes about the thimerosal transition timeline. MedicalDaily will report on both rather than on statements about intent.
Frequently Asked Questions
How much money was released and for what years? $600 million total, covering congressional appropriations of $300 million for each of fiscal years 2025 and 2026.
What is Gavi? A public-private partnership that pools donor funds to buy vaccines at negotiated prices for low- and middle-income countries and to support delivery systems and outbreak stockpiles.
What conditions came with the money? Gavi committed to work toward transitioning away from mercury-containing vaccines, and the United States stated it will not provide U.S. government funding to the World Health Organization through the alliance.
What is thimerosal? A mercury-based preservative used in some multi-dose vaccine vials to prevent contamination after the vial is opened. It was removed from routine U.S. childhood vaccines beginning in 1999.
Does thimerosal cause autism? No. Extensive research has not found evidence of a causal link, and autism diagnosis rates continued rising after its removal from U.S. childhood vaccines.
How did Gavi respond to the WHO restriction? The alliance said WHO's role is already funded through other international donors and that U.S. money will go to vaccine procurement, consistent with past practice.
Does this affect vaccines available in the United States? No. U.S. routine childhood vaccines are already thimerosal-free or available in single-dose presentations. The conditions concern Gavi's international procurement.
